GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been assigned an average recommendation of “Buy” from the seven research firms that are covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $14.20.

GOVX has been the subject of a number of research reports. Alliance Global Partners initiated coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 target price for the company. D. Boral Capital reiterated a “buy” rating and set a $18.00 target price on shares of GeoVax Labs in a research report on Thursday, January 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research report on Friday, November 15th.

Hedge Funds Weigh In On GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC acquired a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs at the end of the most recent quarter. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

GeoVax Labs Stock Performance

NASDAQ GOVX opened at $1.88 on Friday. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The company has a 50-day simple moving average of $2.38 and a 200 day simple moving average of $2.75.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.38. The company had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter last year, the business posted ($4.80) EPS. As a group, analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.